Abstract
Data from 225 multiple myeloma (MM) patients, undergoing peripheral stem cell (PBSC) mobilization with high-dose cyclophosphamide and hematopoietic growth factors, were analyzed for median CD34+ cell count and median time to post-transplant neutrophil (ANC > 500/μ l) and platelet (> 50 000/μ l) recovery according to age groups (20–49, 50–59 and ⩾60 years) and duration of prior therapy (⩽12, 13–24 or >24 months). Fifty-seven of the 225 patients were ⩾60 years. No difference in either the median number of CD34+ cells collected or time to engraftment occurred between age groups, when adjusted for duration of prior therapy. These data support the concept that autotransplants can be performed safely in patients ⩾60 years and that these patients should not be excluded from the most effective treatment modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guba, S., Vesole, D., Jagannath, S. et al. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 20, 1–3 (1997). https://doi.org/10.1038/sj.bmt.1700833
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700833
Keywords
This article is cited by
-
Autologous stem cell transplantation in the elderly including pre- and post-treatment options
Bone Marrow Transplantation (2007)
-
Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis
Bone Marrow Transplantation (2006)
-
Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Bone Marrow Transplantation (2006)
-
High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol
Bone Marrow Transplantation (2006)
-
Autologous stem cell transplantation beyond 60 years of age
Bone Marrow Transplantation (2006)